Company intelligence / Profile preview

Ningbo Shengjian Biomedical Technology

Zhejiang, Chinaadisinsight.springer.com ↗

Ownership: Private
Development stage: Other

Overview

Lead asset CX13-608 is a small molecule proteasome inhibitor in Phase 2 clinical trials for relapsed multiple myeloma. Earlier, it was evaluated in a multicenter, open-label Phase I trial focused on safety and tolerability.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

CX13-608

Unknown

Beyond the preview

Go deeper on Ningbo Shengjian Biomedical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ningbo Shengjian Biomedical Technology.

Explore the full profile